

Company announcement no 11/2023

Interim Report Q2 2023

EBITDA fixed herd prices (FHP) for Q2 2023 increased to 10.236 mEUR (Q2 2022: 5.797 kEUR), corresponding to an EBITDA margin FHP of 28.1% (Q2 2022: 21.0%). The quarterly EBITDA in Q2 2023 increased by 4.439 kEUR (compared to Q2 2022). Mainly driven by improved sales prices, as they in Q2 2023 were 1.62 EUR/kg live weight, up from 1.39 EUR/kg Q2 2022 equal to EUR 5,1m and feed with EUR 0,9m , whereas the LT Subsidy in Q2 2022 effect comparison negative EUR 2,5m, as it was one-off.

Feed prices in Q2 2023 were 288 EUR/T (compared to 302 EUR/T Q2 2022). End June 2023 1.6 mEUR hedging gains are included in Group equity in other reserves, which will be released into EBITDA in Q3 2023.

The herd valuation in Q2 increased by 5,136 kEUR (compared to 31.03.2023). The increase is driven by increasing price in EU, as the EU supply of pork has been reduced during the last 2-3 years. Nevertheless, prices have in Q3 started to decrease from the historical high levels.

Net interest-bearing debt (NIBD) decreased to EUR 56.8m end Q2 2023, being EUR 31.0m lower than Q4 2020 when bond was issued (87.8 mEUR). Nevertheless, the following need to be considered EUR 1,6 from hedging transactions which will be included in EBITDA in Q3 2023. The EUR 75m bond duration ends Q4 2025, hence having very stable financing. NIBD split is 2,8 mEUR in Russia and 54,0 mEUR in Denmark/Lithuania. Outstanding bonds is 68,7 mEUR and own bonds end Q2 2023 is 12,3 mEUR.

Liquidity position, In order to utilize our current liquidity position and to ensure that Bondholders receive a partial redemption of Bonds in the short-term future instead of waiting for the cash sweep in accordance with the Bond Terms (i.e. potentially not before 31 May 2024), Idavang proposes to apply an amount of EUR 6,500,000 towards partial redemption of Bonds as an advance payment of future excess cash sweeps (with the same mechanics as the previous EUR 4,800,000 partial redemption made in January 2023).

The EUR 6,500,000 amount reflects our estimate of the Cash Sweep Amount for full year 2023 (after deducting the remaining amount of the EUR 4,800,000 advance payment made in connection with the amendment agreement no. 2) and corresponds to approx. 10 % of the outstanding principal of the Bonds.

If supported by major Bondholders after sounding with such, Idavang suggests to implement the proposal as a written resolution and will publish a summons to such written resolution separately. In that case, investors will be requested to vote in accordance with the procedure described therein. If the proposal is passed by the requisite number of bondholders, we will make the redemption and corresponding payments no later than 10 Business Days after final approval.

In December 2022 Company Announcement no 19/2022 was published. According to the announcement the Board of Directors and the Executive Boards are conducting a strategic review of the Group's presence in Russia. As part of the strategic review the options for the future of the Group's Russian activities are explored, including a potential sale of the business.

No conclusion of the process has been reached, at the date of signing submitting this interim report.

Selected financial highlights and key ratios

EUR millions	Q2 2023	Q2 2022	6M 2023	6M 2022	2022
Total revenue	36.421	27.608	69.220	48.179	115.219
EBITDA	15.373	974	27.726	8.423	30.245
EBITDA margin	42,2%	3,5%	40,1%	17,5%	26,2%
EBITDA fixed herd price	10.236	5.797	16.171	6.060	21.815
EBITDA margin fixed herd price	28,1%	21,0%	23,4%	12,6%	18,9%
Net income	10.650	-363	18.338	3.145	15.736
Free cash flow	7.760	11.287	11.548	7.635	17.563
Net interest-bearing debt	56.767	78.657	56.767	78.657	66.491

Further information

Bondholders - Claus Baltersen, CEO phone +370 (685) 34 104

Media - Jytte Rosenmaj, Board Member phone +45 26 73 46 99

Finance Calendar 2023

30th November 2023: Q3 Interim report 2023

28th February 2024: Annual report 2023

Forward-looking statements

This interim report contains “forward-looking statements.” Undue reliance should not be placed on forward-looking statements because they relate to and depend on circumstances that may or may not occur in the future, and actual results may differ materially from those in forward-looking statements. Forward-looking statements include, without limitation, statements regarding our business, financial circumstances, strategy, results of operations, financing and other plans, objectives, assumptions, expectations, prospects, beliefs and other future events and prospects. We undertake no obligation and do not intend to publicly update or revise any of these forward-looking statements unless prescribed by law or by stock exchange regulation.

Table of contents

REVIEW	4
Financial Highlights and Key Ratios.....	4
Management's Review	5
Development in segments in Q2 2023	6
Statement by the Board and the Executive Management.....	8
FINANCIAL STATEMENT	9
Income Statement	9
Statement of comprehensive income	9
Assets	10
Liabilities and Equity.....	11
Cash Flow Statement	12
Statement of changes in equity	13
Notes.....	14
Quarterly Financial Highlights and Key Ratios.....	19

Review

Financial Highlights and Key Ratios

EUR '000	Q2 2023	Q2 2022	6M 2023	6M 2022	2022
Income statement					
Revenue	36.421	27.608	69.220	48.179	115.219
EBITDA	15.373	974	27.726	8.423	30.245
EBITDA fixed herd price	10.236	5.797	16.171	6.060	21.815
EBIT	13.692	-773	24.235	4.974	22.252
Financial items, net	-1.590	1.000	-3.177	-622	-3.838
Profit/(loss) for the period	10.650	-363	18.338	3.145	15.736
Cash flow					
Operating activity	6.588	9.850	8.582	6.679	17.750
Investing activity	-418	1.223	-262	-932	-6.792
Financing activity	-858	-8.909	-4.599	-11.106	-15.002
Free cash flow	7.760	11.287	11.548	7.635	17.563
Balance sheet					
Non-current assets	85.661	117.465	85.661	117.465	96.849
Net working capital	39.506	40.892	39.506	40.892	36.002
Net operating assets	125.167	158.357	125.167	158.357	132.851
Total assets	152.612	182.814	152.612	182.814	158.371
Equity	62.856	75.975	62.856	75.975	61.706
Net interest bearing debt	56.767	78.657	56.767	78.657	66.491
Key financials Group					
EBITDA margin	42,2%	3,5%	40,1%	17,5%	26,2%
EBITDA margin - fixed herd prices	28,1%	21,0%	23,4%	12,6%	18,9%
Cash conversion - fixed herd prices	76%	195%	71%	126%	81%
NIBD / EBITDA fixed price LTM	1,8	6,3	2,1	6,3	3,0
Equity ratio	41,2%	41,6%	41,2%	41,6%	39,0%

Management's Review

Income statement

Revenue

The revenue for Q2 2023 was 36,421 kEUR (Q2 2022: 27,608 kEUR) increase of 32%. The increase sale is 22% price and remaining part is increase of volume driven by sales have started from Ostrov farm.

Value adjustment, biological assets

The herd valuation in Q2 increased by 5,136 kEUR (compared to 31.03.2023). The increase is driven by increasing price in EU, as the EU supply of pork has been reduced during the last 2-3 years. Nevertheless, prices have in Q3 started to decrease from the historical high levels.

EBITDA fixed herd prices (FHP)

EBITDA fixed herd prices (FHP) for Q2 2023 increased to 10.236 mEUR (Q2 2022: 5.797 kEUR), corresponding to an EBITDA margin FHP of 28.1% (Q2 2022: 21.0%). The quarterly EBITDA in Q2 2023 increased by 4.439 kEUR (compared to Q2 2022). Mainly driven by improved sales prices, as they in Q2 2023 were 1.62 EUR/kg live weight, up from 1.39 EUR/kg Q2 2022 equal to EUR 5,1m and feed with EUR 0,9m , whereas the LT Subsidy in Q2 2022 effect comparison negative EUR 2,5m, as it was one-off.

Feed prices in Q2 2023 were 288 EUR/T (compared to 302 EUR/T Q2 2022). End June 2023 1.6 mEUR hedging gains are included in Group equity in other reserves, which will be released into EBITDA in Q3 2023.

Net financials

The net interest expenses excluding fx gain is in Q2 2023 1.699 kEUR of which, bond cost is 87% of interest expenses.

Balance Sheet

At 30th June 2023, Idavang's balance sheet amounted to 152,612 kEUR (December 2022: 158,371 kEUR). The equity on 30st June 2023 amounted to EUR 62.9m at an equity ratio of 41% (39% FY2022). The equity increased in H1 2023 with EUR 1,1m, positive result (of EUR 18,3m) being reduced due to weaker RUB (EUR 14,0m) and reduction in hedging reserve (EUR 3,2m).

Net interest-bearing debt (NIBD) decreased to EUR 56.8m end Q2 2023, being EUR 31.0m lower than Q4 2020 when bond was issued (87.8 mEUR). Nevertheless, the following need to be considered EUR 1,6 from hedging transactions which will be included in EBITDA in Q3 2023. The EUR 75m bond duration ends Q4 2025, hence having very stable financing. NIBD split is 2,8 mEUR in Russia and 54,0 mEUR in Denmark/Lithuania. Outstanding bonds is 68,7 mEUR and own bonds end Q2 2023 is 12,3 mEUR.

The networking capital increased with 3,504 kEUR (to 36,002 kEUR 31.12.2022) compared to end 2022. Adjusting for the price increase in commercial herd value of 9,092 kEUR the networking capital decreased with 5,588 kEUR driven by RUB devaluated 26% during 1H 2023 and decreasing inventory volumes in Russia (due to season).

Cash flow

Cash flow from ordinary activities for Q2 2023 increased to 6.588 kEUR (Q2 2022: 9.850 kEUR). The decrease of 3,262 kEUR is mainly related to accounting of matif hedges effecting cash flow negative with 6.811 kEUR compared to Q2 2022, and not even a positive impact from EBITDA FHP of 4.439 kEUR can fully compensate that.

Post Balance Sheet Events

None

Development in segments in Q2 2023

Lithuania

EUR '000	Q2 2023	Q2 2022	6M 2023	6M 2022	2022
Revenue	25.264	19.148	47.916	32.492	72.963
Value adjustment, biological assets	3.118	-1.123	7.420	4.250	8.176
Production costs	-17.784	-16.470	-35.890	-30.807	-66.526
Administrative costs	-516	-543	-1.021	-1.051	-2.124
Other income	892	3.174	1.194	3.468	7.167
Other expense	-69	6	-68	12	-
Operating profit	10.905	4.192	19.551	8.365	19.657
Net Financials	-457	-239	-787	-559	-1.046
Foreign exchange adjustments	-	-	-	-	-
Profit before tax	10.448	3.953	18.764	7.807	18.611
Tax on profit for the year	-1.431	-597	-2.682	-1.178	-2.593
Profit for the period	9.017	3.355	16.082	6.628	16.018



EUR '000	Q2 2023	Q2 2022	6M 2023	6M 2022	2022
Depreciations included in production cost	-626	-657	-1.265	-1.313	-2.562
EBITDA	11.531	4.849	20.816	9.678	22.219
<i>EBITDA fixed herd prices</i>	<i>8.413</i>	<i>5.972</i>	<i>13.396</i>	<i>5.428</i>	<i>14.043</i>

Lithuania accounted for 69 % of Group revenue in Q2 2023 (Q2 2022: 69 %).

EBITDA fixed herd prices reflect that the above EBITDA has been adjusted for the unrealized value adjustment related to biological assets.

The EBITDA fixed herd price for Q2 2023 amounted to 8,413 kEUR, corresponding to an EBITDA margin of 33.3% (Q2 2022: 5.972 kEUR and EBITDA margin 31,1 %). Hence, the EBITDA fixed herd price increased compared to Q2 2022 by 2.441 kEUR, driven by a net of sales improvement, but reduced by negative effects from one-off subsidy in Q2 2022 (2,5 mEUR) and higher feed price effect.

The sales price increased 37 % compared to Q2 2022 to an average 1,88 EUR per kilo slaughter pigs' live weight in Q2 2023 (Q2 2022: 1,38 EUR per kilo live weight slaughter pigs) with an effect of 6,6 mEUR, whereas higher feed prices impact negative (with EUR 1.5m). Cost per kg. (Excluding feed) increased 13% compared to Q2 2022.



Russia

EUR '000	Q2 2023	Q2 2022	6M 2023	6M 2022	2022
Revenue	11.158	8.459	21.304	15.686	42.257
Value adjustment, biological assets	2.018	-3.700	4.135	-1.887	254
Production costs	-9.896	-9.430	-19.909	-16.666	-38.195
Administrative costs	-347	-321	-676	-569	-1.446
Other income	64	128	228	282	412
Other expense	-	-	-	-	0
Operating profit	2.997	-4.863	5.081	-3.155	3.281
Net Financials	-121	-245	-261	-508	-1.259
Foreign exchange adjustments	129	-260	197	121	2.581
Profit before tax	3.006	-5.368	5.017	-3.542	4.602
Tax on profit for the year	-20	8	-39	-29	-85
Profit for the period	2.986	-5.360	4.978	-3.571	4.517



EUR '000	Q2 2023	Q2 2022	6M 2023	6M 2022	2022
Depreciations included in production cost	-1.055	-1.090	-2.226	-2.135	-5.431
EBITDA	4.053	-3.773	7.307	-1.019	8.712
<i>EBITDA fixed herd prices</i>	<i>2.035</i>	<i>-74</i>	<i>3.173</i>	<i>868</i>	<i>8.458</i>

Russia accounted for 31 % of Group revenue in Q2 2023 (Q2 2022: 31 %).

EBITDA fixed herd prices reflect that the above EBITDA has been adjusted for the unrealized value adjustment related to biological assets.

The EBITDA fixed herd price for Q2 2023 amounted to 2,035 kEUR, corresponding to an EBITDA margin of 18.2% (Q2 2022: -74 kEUR and EBITDA margin -0,9 %). Hence, the EBITDA fixed herd price increased compared to Q2 2022 by 2.109 kEUR as a positive effect comes from lower feed prices and higher volume (Ostrov), whereas sales prices effect negative.

The sales price decreased 13 % (in EUR) compared to Q2 2022 to an average 1,24 EUR per kilo slaughter pigs' live weight in Q2 2023 (Q2 2022: 1,42 EUR per kilo live weight slaughter pigs) with an effect of 1,4 mEUR, whereas lower feed prices (in EUR) impact positive (with EUR 2.7m). Cost per kg. (excluding feed volume) decreased 30% compared to Q2 2022.



Statement by the Board and the Executive Management

The Executive Board and the Board of Directors have presented the interim Report of Idavang A/S. The interim Report has today been considered and adopted.

The Interim Report, which has not been audited or reviewed by the Company's independent auditors, was prepared in accordance with IAS 34 "Interim Financial Reporting" as adopted by the EU and additional Danish disclosure requirements for listed companies.

In our opinion, the Interim Financial Statements give a true and fair view of the financial position of the Group at 30th June 2023 as well as of the results of the Group operations and cash flows for the period 1st Jan – 30th June 2023.

In our opinion, Management's Review gives a true and fair account of the development in the activities and financial circumstances of the Group, of results of operations for the period and of the overall financial position of the Group, and a description of the key risks and uncertainties facing the Group.

Executive Management

Claus Baltersern
CEO

Michael Thuesen Henriksen
CFO

Board of Directors

Niels Hermansen
Chairman

Jytte Rosenmaj

Carsten Lund Thomsen

Claus Baltersen

Ole B. Hansen

Financial Statement

Income Statement

EUR '000	Q2 2023	Q2 2022	6M 2023	6M 2022	2022
Revenue	36.421	27.608	69.220	48.179	115.219
Value adjustment, biological assets	5.136	-4.823	11.555	2.363	8.430
Production costs	-27.680	-25.901	-55.799	-47.473	-104.721
Administrative costs	-1.074	-972	-2.094	-1.856	-4.256
Other income	956	3.302	1.422	3.750	7.579
Other expense	-69	13	-68	12	0
Operating profit	13.692	-773	24.235	4.974	22.252
Net Financials	-1.699	-214	-3.353	-1.888	-6.471
Foreign exchange adjustments	109	1.214	177	1.266	2.633
Profit before tax	12.101	227	21.059	4.352	18.414
Tax on profit for the year	-1.451	-589	-2.721	-1.207	-2.678
Profit for the period	10.650	-363	18.338	3.145	15.736

EUR '000	Q2 2023	Q2 2022	6M 2023	6M 2022	2022
Depreciations included in production cost	-1.681	-1.747	-3.491	-3.449	-7.993
EBITDA	15.373	974	27.726	8.423	30.245
<i>EBITDA fixed herd prices</i>	<i>10.236</i>	<i>5.797</i>	<i>16.171</i>	<i>6.060</i>	<i>21.815</i>

Statement of comprehensive income

EUR '000	Q2 2023	Q2 2022	6M 2023	6M 2022	2022
Profit for the period	10.650	-363	18.338	3.145	15.736
Other comprehensive income					
Exchange adjustments, foreign subsidiaries	-7.507	34.413	-13.950	28.723	5.644
Hedge accounting	-1.619	1.961	-3.238	4.363	582
Other comprehensive income to be reclassified to profit or loss in subsequent periods	-9.126	36.374	-17.188	33.086	6.226
Other comprehensive income not to be reclassified to profit or loss in subsequent periods	-	-	-	-	-
Total comprehensive income	1.525	36.011	1.150	36.231	21.962

Assets

EUR '000	Q2 2023	Q2 2022	6M 2023	6M 2022	2022
Intangible assets	1.172	1.314	1.172	1.314	1.221
Property, Plant and Equipment	68.409	101.877	68.409	101.877	80.880
Biological Assets, Breeding herd	14.875	13.069	14.875	13.069	13.543
Deferred tax	761	761	761	761	761
Financial fixed assets	445	445	445	445	445
Total non-current assets	85.661	117.465	85.661	117.465	96.849
Inventories	9.688	17.788	9.688	17.788	17.395
Biological Assets, Commercial herd	34.454	23.689	34.454	23.689	26.556
Biological Assets, Arable	2.875	4.412	2.875	4.412	1.332
Biological Assets	37.329	28.101	37.329	28.101	27.888
Trade receivables	5.580	5.305	5.580	5.305	3.471
Other receivables	682	2.714	682	2.714	1.723
Prepayments	1.173	1.073	1.173	1.073	693
Income taxes receivables	-	390	-	390	392
Receivables	7.435	9.482	7.435	9.482	6.279
Cash	12.499	9.978	12.499	9.978	9.961
Total current assets	66.951	65.349	66.951	65.349	61.523
Total Assets	152.612	182.814	152.612	182.814	158.371

Liabilities and Equity

EUR '000	Q2 2023	Q2 2022	6M 2023	6M 2022	2022
Share capital	800	800	800	800	800
Exchange adjustments	-43.146	-6.117	-43.146	-6.117	-29.196
Other reserves	1.617	8.636	1.617	8.636	4.855
Retained earnings	103.585	72.656	103.585	72.656	85.247
Equity	62.856	75.975	62.856	75.975	61.706
Borrowings	58.488	66.135	58.488	66.135	58.718
Grants	1.474	2.058	1.474	2.058	1.697
Deferred tax	4.070	1.666	4.070	1.666	2.957
Provisions	-	-	-	-	-
Other non-current liabilities	554	654	554	654	554
Non current liabilities	64.587	70.513	64.587	70.513	63.925
Borrowings	10.778	22.501	10.778	22.501	17.734
Trade payables	9.252	10.257	9.252	10.257	10.570
Income taxes payables	1.900	473	1.900	473	745
Other payables	3.239	3.095	3.239	3.095	3.692
Current liabilities	25.169	36.326	25.169	36.326	32.740
Total liabilities	89.756	106.839	89.756	106.839	96.666
Total Equity and Liabilities	152.612	182.814	152.612	182.814	158.372

Cash Flow Statement

EUR '000	Q2 2023	Q2 2022	6M 2023	6M 2022	2.022
Operating profit/loss	13.692	- 773	24.235	4.974	22.251
Adjustment for non-cash operating items	- 5.074	11.762	- 11.302	4.880	107
	8.617	10.989	12.933	9.854	22.358
Change in working capital incl. herd	- 211	- 1.092	- 1.062	- 1.312	1.777
Cash flow from ordinary activities before financials	8.406	9.897	11.872	8.542	24.135
Net financials	- 1.590	- 214	- 3.229	- 1.888	- 6.605
Corporate tax paid	- 228	167	61	25	220
Cash flow from ordinary activities	6.588	9.850	8.582	6.679	17.750
Cash flow from investing activities	- 418	1.223	- 262	- 932	- 6.792
Proceeds from borrowings	2.103	2.785	2.103	2.785	11.615
Repayments of borrowings	- 2.961	- 11.694	- 6.702	- 13.891	- 26.617
Dividends paid to shareholders	-	-	-	-	-
Surplus on Escrow account	-	-	-	-	-
Cash flow from financing activities	- 858	- 8.909	- 4.599	- 11.106	- 15.002
Cash and cash equivalents primo priod	7.909	5.489	9.962	13.545	13.545
Change in cash and cash equivalents	5.312	2.163	3.721	- 5.359	- 4.044
Exchange adjustments	- 721	2.325	- 1.183	1.792	461
Cash and cash equivalents end priod	12.500	9.978	12.500	9.978	9.962

The group furthermore has 9.0 mEUR overdraft facilities not utilized at period-end (at Jyske Bank and own 12.3 mEUR Idavang Bonds. Cash and cash equivalents end period in Russia equals 7.247 kEUR.

Statement of changes in equity

EUR '000	Share capital	Exchange adjustment	Other reserves	Retained earnings	Total
Equity at 1st January 2023	800	- 29.196	4.855	85.247	61.706
Profit/Loss for the period				10.650	10.650
Other comprehensive income		- 7.507	- 1.619		- 9.126
Total comprehensive income	-	- 7.507	- 1.619	10.650	1.525
Equity at 30th June 2023	800	- 36.703	3.236	95.897	63.231

EUR '000	Share capital	Exchange adjustment	Other reserves	Retained earnings	Total
Equity at 1st January 2021	800	- 34.840	4.273	69.511	39.744
Profit/Loss for the period				15.736	15.736
Other comprehensive income		5.644	582		6.226
Total comprehensive income	800	- 29.196	4.855	85.247	61.706
Dividend					-
Repurchase shares					
Equity at 31st December 2021	800	- 29.196	4.855	85.247	61.706

Notes

Note 1 Basis of preparation and changes to the Group's accounting policies

The interim condensed consolidated financial statements for the 3 months ended 30th June 2023 have been prepared in accordance with Idavang A/S' accounting policies as stated in the latest financial statements for the company and in accordance with IAS 34 "Interim Financial Reporting" as adopted by the EU and additional Danish disclosure requirements for interim financial reporting of listed companies.

The consolidated financial statements are presented in thousand EUR.

The Interim condensed consolidated financial statements do not include all the information and disclosures required in the annual financial statements, and should be read in conjunction with the Group's annual financial statements as at 31st Dec 2022.

The Group's accounting policies is unchanged compared with the Group's annual financial statements as at 31st Dec 2022.

Note 2 Biological assets measured at fair value

The change in the value of biological assets for Q2 2023 is stated in the below table. The total change in fair value is included in revenue reported in the income statement.

EUR '000	Q2 2023	Q2 2022	6M 2023	6M 2022	2022
Commercial herd primo	31.851	20.989	26.556	14.889	14.889
Change in fair value	4.113	-1.578	10.535	5.118	11.217
Exchange adjustments	-1.510	4.277	-2.637	3.682	451
Commercial herd ultimo	34.454	23.689	34.454	23.689	26.556
Breeding herd primo	13.923	12.699	13.543	12.094	12.094
Change in fair value	3.382	-480	2.809	18	1.171
Exchange adjustments	-2.430	851	-1.477	958	278
Breeding herd ultimo	14.875	13.069	14.875	13.069	13.543
Herd total primo	45.774	33.688	40.099	26.982	26.982
Change in fair value due to volume	2.358	2.765	1.789	2.773	3.958
Change in fair value due to price	5.136	-4.823	11.555	2.363	8.430
Exchange adjustments	-3.940	5.128	-4.114	4.640	729
Herd total ultimo	49.329	36.758	49.329	36.758	40.099
Crop primo	1.556	1.372	1.332	1.004	1.004
Change in fair value due to volume	1.485	2.149	1.815	2.679	239
Change in fair value due to price	-	-	-	-	-
Exchange adjustments	-166	891	-272	728	89
Crop ultimo	2.875	4.412	2.875	4.412	1.332
Total Biological Assets primo	47.329	35.059	41.431	27.986	27.986
Change in fair value due to volume	3.843	4.913	3.604	5.452	4.196
Change in fair value due to price	5.136	-4.823	11.555	2.363	8.430
Exchange adjustments	-4.106	6.019	-4.386	5.368	818
Total Biological Assets ultimo	52.203	41.170	52.203	41.170	41.431

Note 3 Segment reporting

The group's results break down as follows on segments:

Q2 2023				
EUR '000	Lithuania	Russia	Other / Eliminations	Group
Revenue	25.264	11.158	-	36.421
Value adjustment, biological assets	3.118	2.018	-	5.136
Production costs	- 17.784	- 9.896	-	- 27.680
Administrative costs	- 516	- 347	- 211	- 1.074
Other income	892	64	-	956
Other expense	- 69	-	-	- 69
Operating profit	10.905	2.997	- 211	13.692
Net Financials	- 457	- 121	- 1.121	- 1.699
Foreign exchange adjustments	-	129	- 20	109
Profit before tax	10.448	3.006	- 1.352	12.101
Tax on profit for the year	- 1.431	- 20	-	- 1.451
Profit for the period	9.017	2.986	- 1.352	10.650
EUR '000				
Depreciations included in production cost	- 626	- 1.055	-	- 1.681
EBITDA	11.531	4.053	- 211	15.373
<i>EBITDA fixed herd prices</i>	<i>8.413</i>	<i>2.035</i>	<i>- 211</i>	<i>10.236</i>
Q2 2022				
EUR '000	Lithuania	Russia	Other / Eliminations	Group
Revenue	19.148	8.459	-	27.608
Value adjustment, biological assets	- 1.123	- 3.700	-	- 4.823
Production costs	- 16.470	- 9.430	-	- 25.901
Administrative costs	- 543	- 321	- 109	- 972
Other income	3.174	128	-	3.302
Other expense	6	-	7	13
Operating profit	4.192	4.863	- 102	773
Net Financials	- 239	- 245	269	- 214
Foreign exchange adjustments	-	260	1.474	1.214
Profit before tax	3.953	5.368	1.642	227
Tax on profit for the year	- 597	8	-	- 589
Profit for the period	3.355	5.360	1.642	363
EUR '000				
Depreciations included in production cost	- 657	- 1.090	-	- 1.747
EBITDA	4.849	3.773	- 102	974
<i>EBITDA fixed herd prices</i>	<i>5.972</i>	<i>74</i>	<i>- 102</i>	<i>5.797</i>

6M 2023				
EUR '000	Lithuania	Russia	Other / Eliminations	Group
Revenue	47.916	21.304	-	69.220
Value adjustment, biological assets	7.420	4.135	-	11.555
Production costs	- 35.890	- 19.909	-	- 55.799
Administrative costs	- 1.021	- 676	- 397	- 2.094
Other income	1.194	228	-	1.422
Other expense	- 68	-	-	- 68
Operating profit	19.551	5.081	- 397	24.235
Net Financials	- 787	- 261	- 2.305	- 3.353
Foreign exchange adjustments	-	197	20	177
Profit before tax	18.764	5.017	- 2.723	21.059
Tax on profit for the year	- 2.682	- 39	-	- 2.721
Profit for the period	16.082	4.978	- 2.723	18.338
EUR '000				
Depreciations included in production cost	- 1.265	- 2.226	-	- 3.491
EBITDA	20.816	7.307	- 397	27.726
<i>EBITDA fixed herd prices</i>	<i>13.396</i>	<i>3.173</i>	<i>- 397</i>	<i>16.171</i>
6M 2022				
EUR '000	Lithuania	Russia	Other / Eliminations	Group
Revenue	32.492	15.686	-	48.179
Value adjustment, biological assets	4.250	- 1.887	-	2.363
Production costs	- 30.807	- 16.666	-	- 47.473
Administrative costs	- 1.051	- 569	- 236	- 1.856
Other income	3.468	282	-	3.750
Other expense	12	-	-	12
Operating profit	8.365	- 3.155	- 236	4.974
Net Financials	- 559	- 508	- 821	- 1.888
Foreign exchange adjustments	-	121	1.145	1.266
Profit before tax	7.807	- 3.542	87	4.352
Tax on profit for the year	- 1.178	- 29	-	- 1.207
Profit for the period	6.628	- 3.571	87	3.145
EUR '000				
Depreciations included in production cost	- 1.313	- 2.135	-	- 3.449
EBITDA	9.678	- 1.019	- 236	8.423
<i>EBITDA fixed herd prices</i>	<i>5.428</i>	<i>868</i>	<i>- 236</i>	<i>6.060</i>

2022				
EUR '000	Lithuania	Russia	Other / Eliminations	Group
Revenue	72.963	42.257	-	115.219
Value adjustment, biological assets	8.176	254	-	8.430
Production costs	- 66.526	- 38.195	-	- 104.721
Administrative costs	- 2.124	- 1.446	- 686	- 4.256
Other income	7.167	412	-	7.579
Other expense	-	0	-	0
Operating profit	19.657	3.281	- 686	22.252
Net Financials	- 1.046	- 1.259	- 4.166	- 6.471
Foreign exchange adjustments	-	2.581	52	2.633
Profit before tax	18.611	4.602	- 4.799	18.414
Tax on profit for the year	- 2.593	- 85	-	- 2.678
Profit for the period	16.018	4.517	- 4.799	15.736
EUR '000				
Depreciations included in production cost	- 2.562	- 5.431	-	- 7.993
EBITDA	22.219	8.712	- 686	30.245
<i>EBITDA fixed herd prices</i>	<i>14.043</i>	<i>8.458</i>	<i>- 686</i>	<i>21.815</i>

Note 4 Summary of bond terms

Issuer	Idavang A/S
Security package:	(i) share pledges over Guarantors and Russian operating companies, (ii) mortgages over substantially Lithuanian real estate, (iii) Danish registered negative pledges, (iv) account pledge over IFC Deposit account and (v) assignment over intra-group loan (RUB 0.5bn - reduced from 0.9b RUB) from the
Original Guarantors:	Rus Invest Aps, Rurik A/S, Pskov Invest Aps, Idavang Russia A/S, UAB Idavang
Status of the bond:	Senior secured
Currency:	EUR
Initial debt amount:	EUR 75 millions
Other facilities:	Super senior RCF up to 9 mEUR, governed under an inter-
Tenor	5 years
Pricing:	3m EURIBOR + 725 bps p.a., quarterly interest payments, EURIBOR floor of 0.0%
Rating:	Unrated
Call options:	Non call during the first 30 months, then 50/33/25/10/0 after 30/36/42/48/57 Cash sweep of 50% of Free cash flow at 102.3925, starting from 2021
Incurrence test	NIBD/EBITDA LTM fixed herd price (net leverage) of 3.00 and
Restricted payments	No financial support (by way of loans, capital or similar) by the Issuer to Russian subsidiaries, except if funded by the super senior facility or if the incurrence test is met (excluding the IFC Deposit from Net Interest Bearing Debt)
Information covenants:	Annual audited statements, quarterly unaudited reports
Change of control:	Investor put at 101%
Listing of bonds:	Nasdaq Copenhagen
Trustee:	Nordic Trustee
Governing law:	Danish law

Quarterly Financial Highlights and Key Ratios

EUR '000	Q2 2023	Q1 2023	Q4 2022	Q3 2022	Q2 2022	Q1 2022
Income statement						
Revenue	36.421	32.799	34.868	32.172	27.608	20.571
EBITDA	15.373	12.353	8.132	13.690	974	7.448
EBITDA fixed herd price	10.236	5.935	5.292	10.463	5.797	263
EBIT	13.692	10.543	5.746	11.532	- 773	5.747
Financial items, net	- 1.590	- 1.586	- 2.757	- 458	1.000	- 1.622
Profit/(loss) for the period	10.650	7.687	2.687	9.905	- 363	3.507
Cash flow						
Operating activity	6.588	1.994	3.066	8.005	9.850	- 3.171
Investing activity	- 418	156	- 2.029	- 3.831	1.223	- 2.155
Financing activity	- 858	- 3.740	- 1.660	- 2.236	- 8.909	- 2.197
Free cash flow	7.760	3.788	2.565	7.363	11.287	- 3.652
Balance sheet						
Non-current assets	85.661	90.930	96.849	113.257	117.465	89.582
Net working capital	39.506	39.001	36.002	45.715	40.892	36.149
Net operating assets	125.167	129.931	132.851	158.972	158.357	125.732
Total assets	152.612	151.794	158.371	187.100	182.814	143.444
Equity	62.856	61.331	61.706	83.839	75.975	39.963
Net interest bearing debt	56.767	63.517	66.491	71.045	78.657	82.475
Key financials Group						
EBITDA margin	42,2%	37,7%	23,3%	42,6%	3,5%	36,2%
EBITDA margin - fixed herd prices	28,1%	18,1%	15,2%	32,5%	21,0%	1,3%
Cash conversion	75,8%	63,8%	48,5%	70,4%	194,7%	-1388,9%
NIBD / EBITDA fixed price LTM	1,8	2,3	3,0	4,6	6,3	6,4
Equity ratio	41,2%	40,4%	39,0%	44,8%	41,6%	27,9%

Appendix / Production information

	Q2 2023	Q1 2023	Q4 2022	Q3 2022	Q2 2022	Q1 2022
Number of Sows average						
Lithuania	15.234	14.983	14.959	15.196	15.204	15.296
Russia	10.399	10.429	10.568	10.161	9.215	7.830
Total	25.633	25.412	25.527	25.357	24.419	23.126
Pigs sold (slaughterpigs, Weaners and Sows)						
Lithuania	116.257	118.291	118.565	117.409	121.517	118.165
Russia	79.567	69.927	75.818	57.475	52.284	53.960
Total	195.824	188.218	194.383	174.884	173.801	172.125
Displacement						
Lithuania	3.937	- 2.140	- 1.339	1.779	- 2.308	2.952
Russia	5.518	10.384	6.594	16.603	12.694	894
Total	9.455	8.244	5.255	18.382	10.386	3.846
Russia, Ostrov						
Total production						
Lithuania	120.194	116.151	117.226	119.188	119.209	121.117
Russia	85.085	80.311	82.412	74.078	64.978	54.854
Total	205.279	196.462	199.638	193.266	184.187	175.971
Feed cost kEUR						
Lithuania	- 12.612	- 12.784	- 12.833	- 12.067	- 11.420	- 9.375
Russia	- 6.401	- 6.578	- 8.416	- 8.548	- 6.676	- 4.742
Total	- 19.013	- 19.363	- 21.249	- 20.615	- 18.096	- 14.117
Feed conversion kg/kg						
Lithuania	2,80	2,84	2,80	2,79	2,78	2,86
Russia	2,76	2,77	2,84	2,95	2,86	2,84
Group	2,78	2,81	2,81	2,85	2,81	2,85